Precidian ETFs Trust GSK plc (GSKH)

Key Updates

GSKH recovered 2.68% to $71.63 since the June 1 report, partially reversing the prior period's 3.54% decline and demonstrating resilience above the $70 support level. The rebound coincides with significant strategic developments in GSK's oncology portfolio, including a collaboration with Halozyme for subcutaneous oncology formulations that expands GSK's technological capabilities in antibody drug conjugates. The YTD performance of +5.02% maintains positive momentum despite recent volatility, while the 6-month gain of 3.65% reflects steady institutional accumulation in the underlying GSK equity.

Current Trend

GSKH trades at $71.63, representing a 5.02% YTD gain and establishing a trading range between $67-$73 over the past two months. The recent recovery from the June 1 low of $69.76 confirms the $70 level as near-term support, while the $72-$73 zone continues to act as resistance. Short-term momentum has turned positive with the 1-day gain of 1.89% and 1-month advance of 2.35%, though the 5-day decline of 1.06% reflects ongoing consolidation. The price action suggests investors are digesting GSK's strategic oncology initiatives while awaiting catalysts from the company's expanding pipeline.

Investment Thesis

The investment case for GSKH centers on GSK's strategic transformation into a diversified pharmaceutical leader with strengthened oncology capabilities. Following Dame Emma Walmsley's 2018 Tesaro acquisition, GSK has systematically rebuilt its cancer business through targeted M&A, including the 2022 Sierra Oncology deal and the 2025 Hengrui Pharma agreement valued at up to $12 billion for 12 drug candidates. The oncology segment generated £2 billion in 2025 sales with 43% year-on-year growth, driven by Zejula and Jemperli's combined £1.4 billion contribution. The recent Halozyme partnership marks GSK's first entry into subcutaneous ADC delivery, positioning the company to leverage advanced drug delivery technologies across multiple promising oncology targets with the first clinical trial expected in 2026. With four marketed oncology drugs and over a dozen pipeline candidates utilizing cutting-edge platforms including T-cell engagers and RNA-based therapies, GSK is establishing a differentiated position in high-growth oncology segments that should drive sustained revenue expansion and multiple re-rating.

Thesis Status

The investment thesis strengthens materially with the Halozyme collaboration announcement. This partnership validates GSK's oncology strategy by expanding addressable markets into subcutaneous ADC delivery—a technology already integrated into ten commercialized products across 100+ global markets. The agreement structure, featuring upfront payments, milestone payments, and royalties on net sales, demonstrates GSK's commitment to building a comprehensive oncology platform rather than pursuing isolated assets. The timing of the first clinical trial in 2026 provides near-term catalysts, while the option for additional future drug targets creates optionality for portfolio expansion. Combined with the 43% oncology revenue growth reported in 2025 and the robust pipeline of 12+ candidates, GSK's transformation from a company that exited oncology a decade ago to a credible competitor in advanced cancer therapeutics is progressing ahead of expectations. The $70 support level holding during recent market volatility suggests institutional investors recognize the strategic value creation underway.

Key Drivers

The primary catalyst is the Halozyme ENHANZE collaboration for subcutaneous oncology formulations, which expands GSK's technological capabilities into rapid, large-volume subcutaneous delivery for ADCs and other oncology targets. This represents a strategic inflection point as GSK becomes the first major pharmaceutical company to pursue subcutaneous ADC delivery at scale. Secondary drivers include the ongoing momentum in GSK's existing oncology portfolio, which achieved £2 billion in 2025 sales with 43% growth, demonstrating commercial execution capability. The broader market context shows sustained institutional confidence, with hedge fund redemptions at five-year lows of 1.56% in May 2026, indicating stable capital allocation to equity strategies. Additionally, the expansion of active ETF products, including PGIM's launch of diversified U.S. equity strategies, creates incremental demand for quality pharmaceutical holdings like GSK.

Technical Analysis

GSKH established a clear trading range between $67-$73 over the past eight weeks, with the current price of $71.63 positioned in the upper half of this range. The recent bounce from $69.76 on June 1 confirms $70 as a significant support level tested three times since late April, while resistance remains at $72-$73 where the security peaked in mid-May. The YTD gain of 5.02% outpaces the 3.65% six-month return, indicating accelerating momentum in 2026. Short-term indicators show mixed signals: the 1-day surge of 1.89% and 1-month gain of 2.35% suggest bullish momentum, while the 5-day decline of 1.06% reflects normal consolidation. Volume patterns during the recent recovery suggest institutional accumulation rather than retail speculation. A sustained break above $73 would target the $75-$76 zone, while a failure at $70 could retest the April lows near $67. The price action since the Halozyme announcement indicates investors are positioning for the 2026 clinical trial initiation as a potential catalyst for range expansion.

Bull Case

• Transformative Halozyme partnership expands addressable market: The collaboration for subcutaneous ADC delivery positions GSK as the first major pharmaceutical to pursue this technology at scale, with ENHANZE already integrated into ten commercialized products across 100+ markets, creating significant competitive advantages and revenue optionality through milestone payments and royalties.
• Accelerating oncology revenue growth validates strategic transformation: GSK's cancer business generated £2 billion in 2025 with 43% year-on-year growth, demonstrating commercial execution capability while Zejula and Jemperli contributed £1.4 billion in combined sales, establishing a substantial revenue base for continued expansion.
• Robust pipeline with 12+ oncology candidates provides multiple shots on goal: GSK's portfolio includes four marketed drugs and over a dozen pipeline candidates utilizing advanced platforms including T-cell engagers and RNA-based therapies, creating diversified pathways to sustained revenue growth beyond current products.
• Strategic M&A track record demonstrates disciplined capital allocation: The $5.1 billion Tesaro acquisition in 2018, $1.9 billion Sierra Oncology deal in 2022, and up to $12 billion Hengrui Pharma agreement in 2025 show systematic portfolio building with immediate commercial impact, suggesting management's ability to identify and integrate value-accretive assets.
• Near-term clinical catalysts with 2026 trial initiation: The first Halozyme collaboration clinical trial projected to initiate in 2026 provides a tangible near-term catalyst for investor sentiment and potential data readouts that could validate the subcutaneous ADC approach.

Bear Case

• Execution risk in rebuilding oncology capabilities after decade-long absence: Despite recent progress, GSK is re-entering oncology after more than a decade away, competing against established players with deeper expertise and larger commercial infrastructures in a highly competitive therapeutic area with significant clinical and regulatory hurdles.
• Heavy reliance on acquired assets rather than internal innovation: GSK's oncology rebuild depends primarily on external acquisitions including Tesaro ($5.1 billion), Sierra Oncology ($1.9 billion), and Hengrui Pharma (up to $12 billion), raising questions about sustainable competitive advantages and the company's ability to generate differentiated internal R&D productivity.
• Clinical trial uncertainty with unproven subcutaneous ADC technology: The Halozyme collaboration represents GSK's first entry into subcutaneous ADC delivery, an unproven approach with no established clinical precedent, creating significant execution risk and potential for costly failures in the 2026 trial initiation.
• Concentration risk in two key oncology products: The £1.4 billion in combined sales from Zejula and Jemperli represents 70% of the £2 billion total oncology revenue, creating vulnerability to competitive pressures, patent expirations, or clinical setbacks in these core franchises.
• Limited near-term price momentum with established resistance: GSKH has failed to sustain moves above $72-$73 multiple times over the past two months, with the current price of $71.63 still 5% below recent highs, suggesting institutional investors remain cautious about valuation despite strategic progress and requiring significant catalysts to break through technical resistance.